Genelux (GNLX) Operating Income (2022 - 2026)
Genelux's (GNLX) quarterly Operating Income came in at -$9.2 million in Q1 2026, down 17.34% year-on-year from -$11.1 million in Q1 2025, and up 2.56% quarter-over-quarter from -$9.4 million in Q4 2025.
Genelux (GNLX) Operating Income (2022 - 2026) Analysis & Trends
Genelux's Operating Income history runs 5 years deep, the most recent figure standing at -$9.2 million for Q1 2026.
- On a quarterly basis, Operating Income fell 17.34% year-over-year to -$9.2 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 10.1% decrease from a year earlier, with the FY2025 full-year figure at -$33.2 million, down 4.79% from the prior year.
- Operating Income rose to -$9.2 million in Q1 2026 per GNLX's latest filing, from -$9.4 million in the prior quarter.
- Across five years, Operating Income topped out at $6.3 million in Q3 2022 and bottomed at -$9.7 million in Q4 2024.
- The 5-year median for Operating Income is -$7.0 million (2023), against an average of -$6.3 million.
- Across the five-year window, Operating Income slumped 183.65% in 2023 and grew 3.68% in 2025, its largest moves.
- Year by year, Operating Income stood at -$3.1 million in 2022, then slumped by 126.28% to -$7.0 million in 2023, then tumbled by 39.24% to -$9.7 million in 2024, then grew by 3.45% to -$9.4 million in 2025, then climbed by 2.56% to -$9.2 million in 2026.
- Per Business Quant, the three latest GNLX Operating Income figures stand at -$9.2 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 472.68 Bn | 467.89 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 122.24 Bn | 114.99 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.33 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 55.93 Bn | 50.75 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.59 Bn | 34.58 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -9.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.17 Mn |
| Dec 31, 2025 | -9.41 Mn |
| Sep 30, 2025 | -8.19 Mn |
| Jun 30, 2025 | -7.79 Mn |
| Mar 31, 2025 | -7.82 Mn |
| Dec 31, 2024 | -9.75 Mn |
| Sep 30, 2024 | -6.94 Mn |
| Jun 30, 2024 | -6.89 Mn |
| Mar 31, 2024 | -8.12 Mn |
| Dec 31, 2023 | -7.00 Mn |
| Sep 30, 2023 | -5.31 Mn |
| Jun 30, 2023 | -5.40 Mn |
| Mar 31, 2023 | -6.46 Mn |
| Dec 31, 2022 | -3.09 Mn |
| Sep 30, 2022 | 6.34 Mn |